ALK and non-small cell lung carcinoma: To investigate the difference in survival of patients with advanced ALK‐positive NSCLC after crizotinib progression under different treatment patterns, we retrospectively analyzed the clinical data of 128 patients who received crizotinib as initial ALK‐TKI and demonstrated the clinical outcomes of different sequential patterns following crizotinib resistance.